Introduction
Hospitalizations and mortality in acute myocardial infarction (AMI) have declined considerably in the general population in the past 4 decades due to improvements in AMI care and use of evidence-based prevention therapies. [1] [2] [3] [4] However, racial and ethnic disparities in outcomes persist, as the reduction of these outcomes in racial and ethnic minorities is much smaller with these groups continuing to experience an excessive burden of coronary artery disease. [1] [2] [3] [4] Recent studies have also shown that women are at higher risk of mortality after AMI than men.
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Differences in gender and racial/ethnic outcomes may be due in part to gender and racial differences in the aggressive use and timely initiation of medical treatments in the earlier management of AMI during hospital admission [5] [6] [7] [9] [10] [11] [12] Moreover, the benefit of the evidence-based preventive therapies not only relies on initiation but also on long-term adherence to therapies. [13] [14] [15] Clinical guidelines support the longterm use of evidence-based pharmacologic therapies following AMI for secondary prevention, including a -blocker, a lipid lowering agent, an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), and low-dose aspirin. 16, 17 Nonetheless, both initial use and long-term adherence following AMI have been shown to be alarmingly low in general. Some patients never fill their first prescription after discharge. 18 One year after hospital discharge, approximately 50% of Medicare patients, prior to implementation of Medicare Part D, have been shown to be non-adherent to statins, -blockers, and ACEI/ARB treatments. 19, 20 If there are significant differential use and adherences to the preventive therapies, these differences may also contribute considerably to the racial/ethnic and gender disparities in health outcomes after AMI.
Lack of pharmacy benefit and low quality care services may contribute to racial/ethnic differences in using preventive therapies. [21] [22] [23] It is unclear whether gender and racial/ethnic gaps management of AMI during hospital admission [5] [6] [7] [9] [10] [11] [12] Moreover, the benefit of the evidence-based preventive therapies not only relies on d n nit it tia ia iati ti tio on on b b but ut ut als so o o o on on long-term adherence to ther er erap api ies. [13] [14] [15] Clinica ca al gu guid id ide el e ines support the longe erm m m use of ev vid id den en ence e-b -b -bas as sed ed ed p p pha h harm rm mac ac col ol log gic t t the e erap pie es fo fo oll ll low ow win n ng g AM AM AMI I fo fo for se sec co con nd ndar ar ry y y pr pr p e ev ven en enti i tion on on, , still exist in the use of and patient adherence to evidence-based therapies for secondary prevention post-AMI compared with findings prior to the Medicare Part D program for pharmacy benefits and years after implementation of the Get With The Guidelines (GWTG) program. 24 This is particularly important in the elderly since the prevalence of AMI is highest in this population. Therefore, the aim of our study was to assess whether there were gender and racial/ethnic gaps in the use of and patient adherence to evidence-based preventive therapy in a large national cohort of elderly Medicare Part D beneficiaries following AMI in 2008. In addition, we explored whether follow-up with a cardiologist or primary care physician and the total patient out-pocket costs for the 3 therapies post-AMI discharge affects the association between gender and race/ethnicity and adherence to the therapies.
Methods

Setting and Participants
All Medicare beneficiaries satisfying the following criteria were included in the cohort: 1) 65 years of age; 2) continuous enrollment for at least 12 months before and after the index AMI hospitalization in the Medicare fee-for-service and prescription Part D benefits; 3) hospitalization for the index AMI between 1/1/2008 and 12/31/2008 and surviving at least 30 days post-discharge; and 4) discharge to home or to skilled-nursing and long-term care facilities and had prescription claims within 30 days after discharge. A 30-day post-discharge window was chosen to ensure that the prescription fills were most likely related to the AMI event itself.
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The Center for Medicare and Medicaid Services (CMS) Medicare Chronic Condition Data Warehouse (CCW) enrollment summary, inpatient, outpatient, skilled nursing facility, physician office visits, and prescription Part D event service claims files were data sources for between gender and race/ethnicity and adherence to the therapies.
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http://circ.ahajournals.org/ Downloaded from this study. To obtain the index AMI hospitalization, individuals were identified if they had an international classification of disease (ICD)-9 code of 410.x1 in either the primary or secondary discharge diagnosis field in the Medicare inpatient claims. Specifically, each patient's first instance of AMI hospitalization within the study period was defined as the index AMI hospitalization. The study was approved by the Institutional Review Board of the University of North Carolina at Chapel Hill.
Race/Ethnicity and Gender Identification
Due to historical issues in how race/ethnicity has been captured in CMS enrollment file, the accuracy of race/ethnicity for non-black minorities has been low, and many non-black minorities have been misclassified into the 'other' category in the CMS enrollment file. 25-28 A 2-step approach was implemented to identify patient race/ethnicity to address this issue. 25, 28, 29 Patient race/ethnicity was first classified using the race/ethnicity status in the Medicare enrollment files.
If the patient's race/ethnicity was classified as 'Unknown' or 'Other' in the CMS enrollment file, they were then reclassified to either 'white', 'black', 'Hispanic', 'Asian', or "Other" based on the race/ethnicity status if defined by the Research Triangle Institute (RTI) race/ethnicity first and last name algorithm variable in the Medicare files, which has been shown to increase accuracy of identification. 25, 28, 29 This method increases sensitivity of race/ethnicity categorization from 29.5 to 76.6% for Hispanic and from 54.7 to 79.2% for Asian and Pacific Islander beneficiaries, with no loss of specificity, and Kappa coefficients up to 0.80 compared to self-reported race/ethnicity. 25, 28 Patient gender was identified by the CMS enrollment file. After gender identification, 10 race/ethnic and gender groupings were created (i.e., white men, white women, black men).
Measure of Preventive Therapy Use after AMI
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Preventive therapy use was defined as filling a prescription within 30 days after the index AMI discharge for any ACEIs/ARB, -blocker, or statin respectively. If an individual had a prescription for a drug within the therapeutic class with a remaining supply greater than 30 days prior to the index AMI admission and filled a prescription for that therapy within 60 days after discharge, that therapy was also classified as therapy use post-AMI. Prescription drug use was identified through national drug codes in the Part D prescription event files in the CCW.
Measure of Adherence to the Preventive Therapies
Adherence to each preventive therapy was calculated as the proportion of days covered by the prescription supply calculated from the prescription refill records in the prescription Part D claims in the 12 months post-AMI discharge (or until death if occurring within 12 months)
among patients who had the respective preventive therapy within 30 days after AMI discharge.
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The adherence measure was also adjusted for overstock of prescription supply in the prescription refills and hospital stays during the study period after AMI discharge. Conforming to current literature, a patient was defined as adherent if the patient had 80% of days covered with prescription supply in the study period.
15, 30
Baseline Characteristics/Covariates
Patient sociodemographic information was ascertained from the CCW enrollment summary files at baseline. These characteristics included age, Census average household income at ZIP code residence, status in the Medicare Part D benefit plan coverage gap ("doughnut-hole") prior to index-AMI admission, and Medicare and Medicaid dual eligibility status. The "doughnut-hole" refers to the coverage gap between the initial coverage limit and the catastrophic-coverage threshold in the Medicare Part D program, whereby the beneficiary's cost-sharing percentage is higher in the "doughnut-hole". Patient discharge location (e.g., home versus skilled nursing claims in the 12 months post-AMI discharge (or until death if occurring within 12 12 2 m m mon n nth th ths) s) s)
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Statistical Analysis
The distribution of patient sociodemographic and clinical characteristics among those who had the 3 preventive therapies post-AMI discharge was described. Multivariable logistic regression models were applied to examine gender and racial/ethnic differences in the initial use and patient adherence of the 3 preventive therapies at 12-months post-index AMI hospitalization, respectively. The multivariable models assessed the associations (odds ratio) between each racial/ethnic and gender group versus white men as the reference and the use and adherence to preventive therapy, adjusting for all measured patient baseline sociodemographic and clinical characteristics. The impacts of follow-up with cardiologist/primary care physician and total outof-pocket costs for the therapies on the gender and racial/ethnic gaps in adherence to the therapies were assessed by additionally adjusting for the 3 variables in the models.
Statistical significance was determined at a two-sided alpha < 0.05 level. All analyses were conducted using SAS 9.2 (Cary, NC).
Results
There were 85,017 individuals included in the final cohort. The distribution of medication use by patient race/ethnicity and gender groups to each characteristics. The impacts of follow-up with cardiologist/primary care physicia ia an n n an a a d d d to to tota ta tal l l ou outof-pocket costs for the therapies on the gender and racial/ethnic gaps in adherence to the h her er rap ap apie ie ies s we we w r r re a ass ss sse es essed by additionally adjustin ng g g fo o or the 3 variab ble le l s in n t t th he he models. Table 2 ).
Among all those receiving respective therapies, 63% were adherent to ACEIs/ARBs, 66% were adherent to -blockers, and 66% were adherent to statins over 12 months following index AMI discharge. The distribution of adherence by patient race/ethnicity and gender categories to each therapy is displayed in A Amo mo mon ng ng a a al ll t tho hose se r re ecei ei eivi vi ing ng ng r r re esp sp pec ec cti ti tiv ve ve t t the he h r ra api pi pies s s, , 63 63 63% % % we we w r r re a a adh dh d e e ere en ent t to to t A A ACE CE CEI I Is/A A AR RB RBs, s s, 66% were adh dh her er eren en nt t t to to t -blo lo lock ck cker er rs, s, s, a and nd n 6 6 66% 6% % w w wer er ere e ad ad dhe he h re e ent nt nt to to to s s sta ta tati ti t ns s s o o ove ve ver r r 12 12 12 m m mon on onth th ths s s fo fo f llowing for all baseline characteristics listed in higher annual income and use of the preventive therapies prior to hospitalization were associated with higher adherence.
Additionally adjusting for follow-up with a cardiologist, a primary care physician, and patient out-of-pocket medication costs for the 3 therapies did not affect the associations between gender and racial/ethnic and groups and adherence to the therapies (Supplemental Table 5 ).
Discussion
In 11 In this study, the gap between minorities (black and Hispanic) and white in prescribing of lipid lowering therapy, ACEIs/ARBs and -blockers at discharge improved over time and was no longer significant after 2004. 11 Our study further particularly black and Hispanic, resoundingly had decreased adherence across the he e t the he h ra ra rapy py py c c cla la lass s es egardless of race/ethnicity, with the exception of white women to statins, despite similar rates of us se e wi wi with th thin in in 3 3 30 0 0 da ays ys ys p post-discharge.
This stu tudy d d dem em mon on onst st stra ra ate te es s th th hat at at d des esp pite e re e ema ar rk k kabl l le e p pro ro og gr res ess s i in n eli li lim mi ina na at ti tin ng ng g g gap ap aps s s in in in i i ini n niti i tiat at ti ion of f f t t tre re reat at atme ment nt nt b b by y e e eld de derl rly y y r ra raci c al al l/e /e / th th thni ni nic c c an an nd d ge ge gen nd nder er er g g gro roup up ups s fo fo foll ll llow ow win in i g g g ac ac acut ute e e AM AM AMI, I, I c c con on nsi si sid d der ra rab bl ble e differences in in c c con on onti ti tinu nu n in in ing g ca ca care re re, su su such ch ch a as me me medi di dica ca ati ti io on n n ad ad dhe here re renc nc nce, e, e s s sti ti till l s s str tr t on on ongl gl gly y y pe pe p rs rs rsis is ist. t. t T T The h h similar highlights that no significant racial/ethnic gaps exist in filling discharge prescriptions for the preventive therapies post-AMI.
However, our study demonstrates that much more still needs to be done to address gaps in continuity of receiving life and cost-saving preventive therapies for older adults of racial/ethnic minorities and women, which to our knowledge has not been elucidated in any other recent research. Our study still found a considerable gap between black and Hispanic patients compared to white patients in long-term adherence to preventive therapies even after adjustment for patient baseline sociodemographic and clinical characteristics. This unexplained gap may suggest racial/ethnic differences in the quality of care issues related to patient adherence.
Notably, this study found that disparities were not equally distributed across all minority groups.
Asians tended to have better adherence than other minority groups. Previous research has indicated that underlying heterogeneity in Asian populations in medication use may exist; it is unclear whether disparities in medication adherence exist within various Asian racial/ethnic subgroups.
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Qualitatively compared with studies assessing adherence to secondary preventive therapies following AMI prior to implementation of the Medicare Part D program 20, 36 , our study suggests that the percentage of patients adherent to these medications has increased slightly.
However, the association between race/ethnic and gender gaps in adherence warrants additional consideration. Our findings suggested a fairly strong association of gender with medication adherence in that women, particularly black and Hispanic, were considerably less likely to be adherent than men post-AMI discharge. Lack of social support, lack of community resources, and individual-level characteristics such as cognitive deficiencies, may also lead to gaps in medication adherence and may differentially affect women of ethnic minorities. 37, 38 In addition, Notably, this study found that disparities were not equally distributed across all m m min in nor orit it ty y y gr gr grou ou o ps ps.
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http://circ.ahajournals.org/ Downloaded from this finding may suggest a continued controversy of women receiving less aggressive treatment with preventive therapies than men for AMI even though the mortality risk after AMI is higher in women. 5, 7, 10, 12 Recent studies have suggested that women tend to present different AMI symptoms (e.g., less chest pain) than men, and women with less chest pain or discomfort were less likely to receive aggressive AMI management and preventive therapies. 8, 39 A gender bias in physicians' attitude has been suggested in the use of secondary prevention therapies in patients with coronary artery disease. 40 This gender bias may also have influenced women's adherence.
Further, the differential gaps across the preventive therapies raised an interesting clinical question. For example, white women were significantly more adherent to statins but less adherent to ACEIs/ARBs and beta-blockers at 12 months post-discharge compared with white men. Asian women had comparatively better adherence to statins and ACEIs/ARBs than toblockers. If therapy use and adherence were influenced in part by physician and patient expectations of treatment benefit and risk, the differential therapy use and adherence may signal different beliefs on benefit and risk of the therapies post-AMI in specific racial/ethnic and gender groups. However, the legitimacy of such beliefs needs to be addressed. Further research may need to study why patients exhibit stronger preferences towards adherence to certain therapy classes but not others following AMI.
Many factors, for example physician follow-up, follow-up lab tests, continuity of care, coordination of care, and medication copayment, have been shown to affect patients' adherence to cardiovascular preventive therapies. [41] [42] [43] In our study, adjusting for follow-up with cardiologist, primary care physician or total patient out-of-pocket medication costs of the 3 preventive therapies did not diminish the gaps in adherence post-AMI, suggesting that adherence post-AMI can be complex. A previous study has suggested that black patients received care adherent to ACEIs/ARBs and beta-blockers at 12 months post-discharge compar red e ed w wit it ith h h wh wh whit it ite e men. Asian women had comparatively better adherence to statins and ACEIs/ARBs than tobl loc oc cke ke ker rs rs. If If If t t th h hera ra apy py py use and adherence were infl l lue ue u n n nced in part by y y ph p ys ys sic ic ici ian and patient ex xpe pectations o of f f t tr tre eatm tm men n nt t be be bene ne nef fit it a a an nd nd r r ris sk k, th he he dif ff fe fer rent nt tia ia al l th th he er er f f f f ap ap py us use e an an and d ad ad adh he here renc nc n e e e m ma may y y si i sign gn gnal di diff ff ffer er eren en ent t be be eli li lief efs s on on n b be en ene ef efit it a and nd nd r r ris is isk k k of of t the he he t t th h hera ra rap pie ie es s po po ost t t-A -A -AMI MI MI i in n n sp sp pec ec e if if fic c c ra raci ci c al al al/e /eth th thn n nic an an nd d g ge gen nd nder groups. Howe we eve ve ver, r, r, t t the he h l leg eg e it t tim im imac ac a y y y of of of s s suc c ch h h be be beli li l ef ef efs s ne ne need ed ds s to to to b b be e e ad ad ddr dr dres es sse se s d. d. d F F Fur ur urth th t er er er r r res es esea ea earc r h may f f f f f f services from lower quality primary care providers than white patients. 22 It is possible that the quality of the visit may be more influential in the gender and racial-ethnic gaps in patient adherence than just a visit itself. Communication between providers and patients is also significantly associated with adherence. 44, 45 Future studies are needed to assess the impact of quality of care on gaps in adherence across gender and racial/ethnic groups.
Care services related to patient adherence involve multiple care providers (cardiologists, primary care physicians, and pharmacists) across institutional and community settings. However, the GWTG program traditionally focuses on the prescribing of evidence-based therapies at hospital discharge. Only recently has the GWTG program begun expanding efforts to the outpatient setting. Our study finding shows a great need for the uptake of such programs focused on medication adherence by healthcare providers serving minorities as well. Also, the program may need to emphasize the equal importance of AMI care quality measures in both men and women.
Our study has several limitations. First, using prescription refill records may not fully represent actual intake of the medication. However, prescription refill records have been shown to have good validity, correlation, and similar sensitivity and specificity as other adherence measurements, including self-report, pill counts, and electronic records. 15, 30, 46 Use of over-thecounter therapies, such as low-dose aspirin, is not available within Medicare Part D prescription data. The accuracy of race/ethnicity identification for non-black minorities has been low in the Medicare enrollment file due to historical issues. To address this limitation, we applied the race/ethnicity status coded by RTI in a first and last names algorithm to improve the sensitivity of non-black minority categorizations in Medicare enrollment data files. Ou Our r r st st stud udy y y h ha has s se seve vera al l l li i imi mi mita ta tat ti tion on ns. s. s F F Fi ir irst t t, , us us sin ng ng p p pre re esc sc scr ript pt ptio ion n re re refi fil ll l r re eco co ord rd rds s s ma ma may y y no no ot fu full lly y epresent actu tu ual al al i int nt ntak ak a e e e of o o t t the he he m med ed edic ic cat at a io o on. n. n. H H How ow owev ev eve er, r r p p pre resc sc scri ri ript pt ptio io on n n re refi fi fill ll l r r rec ec ecor or ords ds h h hav av ave e e be be b en shown and gender gaps in adherence on cardiovascular outcomes were also not examined in this study.
However, the clinical significance of gender and racial/ethnic gaps in adherence to post-AMI preventive therapies is supported by the literature that the lack of medication adherence is associated with an increase in adverse outcomes. 15, 47 Post-AMI patients with low 1-year adherence to statins were shown to have 25% and 12% higher mortality risk compared to patients with high and intermediate 1-year adherence. 15 Similar dose-response adherencemortality association was also observed for -blockers. 15 There are several strengths of this study. This study used a large national cohort from a 
Conclusion
Our study showed no evidence of racial/ethnic/gender differences in the use of -blockers, ACEIs/ARBs, and statins following AMI within 30 days with a few specific exceptions.
However, minority patients, as compared to white patients, were significantly less adherent to the foundation/american heart association task force on performance measures and the american medical association-physician consortium for performance improvement. 
